Intellia Therapeutics (NTLA) Non-cash Items (2016 - 2026)

Intellia Therapeutics (NTLA) has 11 years of Non-cash Items data on file, last reported at $4.1 million in Q1 2026.

• Quarterly Non-cash Items rose 20604.8% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (up 20604.8% YoY) and the FY2025 annual result came in at $4.1 million, up 1069.27% from the prior year.
• Non-cash Items advanced to $4.1 million in Q1 2026 per NTLA's latest filing, from $50000.0 in the prior quarter.
• Across five years, Non-cash Items topped out at $204.9 million in Q1 2022 and bottomed at $20000.0 in Q1 2025.
• The 5-year median for Non-cash Items is $27.6 million (2024), against an average of $51.0 million.
• The widest annual swing landed in 2025, when Non-cash Items slumped 99.93%; it then jumped 20604.8% in 2026.
• Tracing NTLA's Non-cash Items over 5 years: stood at $93.1 million in 2022, then slumped by 61.42% to $35.9 million in 2023, then tumbled by 99.03% to $350000.0 in 2024, then slumped by 85.71% to $50000.0 in 2025, then jumped by 8181.92% to $4.1 million in 2026.
• Per Business Quant, the three latest NTLA Non-cash Items figures stand at $4.1 million (Q1 2026), $50000.0 (Q4 2025), and $11.1 million (Q3 2025).

Peer Comparison